Sea squirts are named for a distinguishing feature: a tube that shoots out water as these filter feeders eat. These creatures look like colorful and rubbery blobs in their natural ocean environment, ...

Inspired by ocean “sea squirts,” Ascidian Therapeutics is floating to the surface with $50 million in series A treasure to fund its ambitions to rewrite RNA for therapeutic benefit. The company, ...

Ascidian Therapeutics has entered a research partnership and licensing agreement with Roche to discover and develop RNA exon editing therapies to treat neurological diseases. The partnership will ...

BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, ...

June 18 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab will team up with privately held biotech Ascidian Therapeutics to develop gene therapies targeting difficult to treat neurological ...

From left to right: Ascidian Therapeutics' Chief Financial & Business Officer Dan Rosan, Senior Vice President and Head of Research Robert Bell, and Chief Medical Officer Jay Barth. Biotechnology ...

Roche has added to its flotilla of RNA alliances, handing Ascidian Therapeutics $42 million upfront to use an alternative to gene editing to treat neurological diseases. The agreement includes up to ...

Roche and Ascidian Therapeutics have partnered to develop RNA exon editing therapies for neurological diseases, with the deal worth over $1.8bn. The research collaboration and licensing agreement ...

Ascidians, along with other urochordates, are the most evolutionary distant group from vertebrates to display definitive chordate-specific characters, such as a notochord, dorsal hollow nerve cord, ...